{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:03:12Z","timestamp":1728360192857},"reference-count":71,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute treatments for migraine and cluster headache are necessary to abort attacks, relieve pain and associated symptoms, and restore an individual's ability to function. Acute headache treatments consist of a variety of medication and nonmedication options. In this article, we discuss the approach to acute treatment of migraine and cluster headache. We summarize the level of evidence to support each acute medication class according to recent systematic reviews and meta-analyses, as well as guideline recommendations from the American Headache Society, American Academy of Neurology, and European Federation of Neurological Society.<\/jats:p>","DOI":"10.1055\/s-0042-1757926","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T23:37:37Z","timestamp":1667432257000},"page":"494-502","source":"Crossref","is-referenced-by-count":0,"title":["Acute Treatment of Headache (Focus on Migraine)"],"prefix":"10.1055","volume":"42","author":[{"given":"Chia-Chun","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi B.","family":"Halker Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"L J Stovner","year":"2018","journal-title":"Lancet Neurol"},{"issue":"S 01","key":"ref2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/head.13300","article-title":"A phase-by-phase review of migraine pathophysiology","volume":"58","author":"D W Dodick","year":"2018","journal-title":"Headache"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/0333102419885381","article-title":"A pilot exploratory study comparing the King-Devick test (KDT) during and between migraine attacks","volume":"40","author":"C-C Chiang","year":"2020","journal-title":"Cephalalgia"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"J Ailani","year":"2021","journal-title":"Headache"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the IHS. The International Classi\ufb01cation of Headache Disorders, 3rd edition","volume":"38","author":"International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-017-0785-3","article-title":"The comorbidity burden of patients with cluster headache: a population-based study","volume":"18","author":"S Joshi","year":"2017","journal-title":"J Headache Pain"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/head.12870","article-title":"How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine","volume":"56","author":"T Pringsheim","year":"2016","journal-title":"Headache"},{"issue":"S 01","key":"ref8","first-page":"18S","article-title":"Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care","volume":"118","author":"M Diamond","year":"2005","journal-title":"Am J Med"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies","volume":"55","author":"M J Marmura","year":"2015","journal-title":"Headache"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.pbr.2020.06.019","article-title":"Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine - the monoclonal antibodies and gepants","volume":"255","author":"C-C Chiang","year":"2020","journal-title":"Prog Brain Res"},{"issue":"24","key":"ref11","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"B Kuca","year":"2018","journal-title":"Neurology"},{"issue":"23","key":"ref12","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults: a systematic review and meta-analysis","volume":"325","author":"J H VanderPluym","year":"2021","journal-title":"JAMA"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.55.6.754","article-title":"Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"S D Silberstein","year":"2000","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2005.03.008","article-title":"Where do triptans act in the treatment of migraine?","volume":"115","author":"A H Ahn","year":"2005","journal-title":"Pain"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/pds.890","article-title":"Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials","volume":"13","author":"D M Ashcroft","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"05","key":"ref16","first-page":"CD008616","article-title":"Zolmitriptan for acute migraine attacks in adults","volume":"CD008616","author":"S Bird","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1468-2982.2001.00169.x","article-title":"Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials","volume":"21","author":"M D Ferrari","year":"2001","journal-title":"Cephalalgia"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2710.2005.00677.x","article-title":"Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials","volume":"30","author":"N Poolsup","year":"2005","journal-title":"J Clin Pharm Ther"},{"issue":"08","key":"ref19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1526-4610.2007.00884.x","article-title":"Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine","volume":"47","author":"L C Chen","year":"2007","journal-title":"Headache"},{"issue":"02","key":"ref20","first-page":"CD008615","article-title":"Sumatriptan (oral route of administration) for acute migraine attacks in adults","volume":"CD008615","author":"C J Derry","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref21","first-page":"CD009665","article-title":"Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults","volume":"CD009665","author":"C J Derry","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","first-page":"CD008541","article-title":"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults","volume":"4","author":"S Law","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"ref23","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"S D Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"S 04","key":"ref24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: a systematic review and network meta-analysis","volume":"55","author":"C Cameron","year":"2015","journal-title":"Headache"},{"issue":"19","key":"ref27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"R B Lipton","year":"2019","journal-title":"JAMA"},{"issue":"23","key":"ref28","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"D W Dodick","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"R B Lipton","year":"2019","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"R Croop","year":"2021","journal-title":"Lancet"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"J Ailani","year":"2021","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2147\/JPR.S244249","article-title":"Ubrogepant in the acute management of migraine: a narrative review","volume":"14","author":"C-C Chiang","year":"2021","journal-title":"J Pain Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201031","article-title":"Efficacy of Ubrogepant in the acute treatment of migraine with mild pain versus moderate or severe pain","author":"R B Lipton","year":"2022","journal-title":"Neurology"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.13766","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II","volume":"60","author":"D W Dodick","year":"2020","journal-title":"Headache"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"R Croop","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/head.14062","article-title":"Real-world efficacy, tolerability, and safety of ubrogepant","volume":"61","author":"C Chiang","year":"2021","journal-title":"Headache"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine","volume":"60","author":"G Berman","year":"2020","journal-title":"Headache"},{"issue":"09","key":"ref38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/0333102420938652","article-title":"Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache","volume":"40","author":"E Navratilova","year":"2020","journal-title":"Cephalalgia"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/HJH.0000000000001649","article-title":"Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline","volume":"36","author":"L Zhai","year":"2018","journal-title":"J Hypertens"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice","volume":"88","author":"I A Mulder","year":"2020","journal-title":"Ann Neurol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/03331024211056250","article-title":"Evaluation and treatment of headache associated with moyamoya disease \u2013 a narrative review","volume":"42","author":"C-C Chiang","year":"2022","journal-title":"Cephalalgia"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0333102419889350","article-title":"Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans","volume":"40","author":"K Knievel","year":"2020","journal-title":"Cephalalgia"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"D L Nelson","year":"2010","journal-title":"Cephalalgia"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"R E Shapiro","year":"2019","journal-title":"J Headache Pain"},{"issue":"04","key":"ref46","first-page":"807","article-title":"Medication-overuse headache","volume":"18","author":"S J Tepper","year":"2012","journal-title":"Continuum (Minneap Minn)"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0333102415593088","article-title":"Treatment of medication-overuse headache: a systematic review","volume":"36","author":"C-C Chiang","year":"2016","journal-title":"Cephalalgia"},{"issue":"19","key":"ref48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000010634","article-title":"Quality improvement in neurology: Headache Quality Measurement Set","volume":"95","author":"M S Robbins","year":"2020","journal-title":"Neurology"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/head.13988","article-title":"Quality improvement in neurology: Headache Quality Measurement Set","volume":"61","author":"M S Robbins","year":"2021","journal-title":"Headache"},{"issue":"01","key":"ref50","first-page":"1","article-title":"Long-term, open-label safety study of rimegepant 75\u2009mg for the treatment of migraine (Study 201): interim analysis of safety and exploratory efficacy (IHC-PO-127)","volume":"39","author":"R B Lipton","year":"2019","journal-title":"Cephalalgia"},{"issue":"S 15","key":"ref51","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1212\/WNL.94.15_supplement.1793","article-title":"Rimegepant 75\u2009mg results in reductions in monthly migraine days: secondary analysis of a multicenter, open label, long-term safety study of rimegepant for the acute treatment of migraine","volume":"94","author":"J S McGinley","year":"2020","journal-title":"Neurology"},{"issue":"14","key":"ref52","doi-asserted-by":"crossref","first-page":"e1409","DOI":"10.1212\/WNL.0000000000200117","article-title":"Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial","volume":"98","author":"T J Schwedt","year":"2022","journal-title":"Neurology"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0333102418811573","article-title":"Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial","volume":"39","author":"D E Chou","year":"2019","journal-title":"Cephalalgia"},{"issue":"08","key":"ref54","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","article-title":"Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial","volume":"80","author":"J Schoenen","year":"2013","journal-title":"Neurology"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1212\/WNL.0000000000005857","article-title":"Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study","volume":"91","author":"C Tassorelli","year":"2018","journal-title":"Neurology"},{"issue":"08","key":"ref56","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/head.13551","article-title":"Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"59","author":"D Yarnitsky","year":"2019","journal-title":"Headache"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s10194-019-1033-9","article-title":"Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications","volume":"20","author":"A M Rapoport","year":"2019","journal-title":"J Headache Pain"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1177\/0333102418762525","article-title":"A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)","volume":"38","author":"A J Starling","year":"2018","journal-title":"Cephalalgia"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/head.14042","article-title":"Remote electrical neuromodulation for acute treatment of migraine in adolescents","volume":"61","author":"A D Hershey","year":"2021","journal-title":"Headache"},{"issue":"S 01","key":"ref61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10072-017-2942-5","article-title":"Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study","volume":"38","author":"L Grazzi","year":"2017","journal-title":"Neurol Sci"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/head.13284","article-title":"Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open-label study","volume":"58","author":"S L Irwin","year":"2018","journal-title":"Headache"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10072-021-05664-7","article-title":"Non-invasive neuromodulation in the acute treatment of migraine: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"O Clark","year":"2022","journal-title":"Neurol Sci"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/head.13665","article-title":"Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review","volume":"60","author":"R Burch","year":"2020","journal-title":"Headache"},{"issue":"10","key":"ref65","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1111\/head.13974","article-title":"Migraine treatment in pregnancy: an American Headache Society survey","volume":"60","author":"K T Hamilton","year":"2020","journal-title":"Headache"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/head.14047","article-title":"The evidence (or lack thereof) for treatment of primary headache during pregnancy and lactation","volume":"61","author":"K T Hamilton","year":"2021","journal-title":"Headache"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/head.14041","article-title":"Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review","volume":"61","author":"I J Saldanha","year":"2021","journal-title":"Headache"},{"issue":"10","key":"ref68","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.mayocp.2020.06.053","article-title":"Effect of migraine on pregnancy planning: insights from the American Registry for Migraine Research","volume":"95","author":"R Ishii","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.mayocp.2020.08.026","article-title":"Migraine headaches and family planning: what we think we know","volume":"95","author":"R B Halker Singh","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1468-1331.2006.01566.x","article-title":"EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias","volume":"13","author":"A May","year":"2006","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-021-01658-z","article-title":"Drug treatment of cluster headache","volume":"82","author":"H C Diener","year":"2022","journal-title":"Drugs"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJM199108013250505","article-title":"Treatment of acute cluster headache with sumatriptan","volume":"325","author":"Sumatriptan Cluster Headache Study Group","year":"1991","journal-title":"N Engl J Med"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1212\/01.WNL.0000046589.45855.30","article-title":"Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study","volume":"60","author":"J A van Vliet","year":"2003","journal-title":"Neurology"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archneur.63.11.nct60002","article-title":"Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study","volume":"63","author":"E Cittadini","year":"2006","journal-title":"Arch Neurol"},{"issue":"07","key":"ref75","first-page":"CD008042","article-title":"Triptans for acute cluster headache","author":"S Law","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1757926.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T03:57:15Z","timestamp":1728273435000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1757926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":71,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1757926","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"type":"print","value":"0271-8235"},{"type":"electronic","value":"1098-9021"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}